Oncternal Therapeutics to Participate in the Cantor Oncology, Hematology & HemeOnc Conference
September 23, 2022 09:00 ET
|
Oncternal Therapeutics
SAN DIEGO, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
September 07, 2022 17:00 ET
|
Oncternal Therapeutics
SAN DIEGO, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2022 Financial Results
August 09, 2022 16:05 ET
|
Oncternal Therapeutics
Interim Phase 1/2 results for zilovertamab plus ibrutinib in MCL presented at ASCO 2022, with ORR of 85% and CR rate of 41%, compare favorably to historical single agent ibrutinib data and support...
Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2022 Financial Results
August 02, 2022 17:00 ET
|
Oncternal Therapeutics
SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics Announces Clinical Trial Collaboration to Advance Zilovertamab Phase 3 Study in combination with Ibrutinib for Patients with MCL
July 14, 2022 16:01 ET
|
Oncternal Therapeutics
Clinical trial collaboration supports global registrational Phase 3 study ZILO-301, to treat patients with relapsed or refractory MCL with zilovertamab plus ibrutinibAgreement is supportive of the...
Oncternal Therapeutics Presents New Preclinical Data from its anti-ROR1 Cell Therapy Collaboration with the Karolinska Institutet at the EHA2022 Congress
June 10, 2022 16:30 ET
|
Oncternal Therapeutics
SAN DIEGO, June 10, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics Presents Rationale and Plans for its Registrational Phase 3 Study Evaluating Zilovertamab in Combination with Ibrutinib at the EHA 2022 Congress
June 10, 2022 09:00 ET
|
Oncternal Therapeutics
SAN DIEGO, June 10, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics to Participate in the Jefferies Healthcare Conference 2022
June 02, 2022 09:00 ET
|
Oncternal Therapeutics
SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
June 01, 2022 17:00 ET
|
Oncternal Therapeutics
SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib at ASCO 2022
May 26, 2022 17:15 ET
|
Oncternal Therapeutics
Updated MCL and CLL data from the CIRLL study are encouraging and continue to improveORR of 85% (23 of 27 evaluable patients) and CR rate of 41% (11 of 27 evaluable patients) for patients with MCL...